Nautilus Biotech Posts Zero Revenue, Widens Q2 Loss to $28.5M

TL;DR

**Nautilus is still burning cash with no revenue, making it a pure speculative bet on future tech.**

AI Summary

Nautilus Biotechnology, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in the development stage for its proteomics platform. The net loss for the three months ended June 30, 2025, was $28.5 million, a slight increase from the $27.9 million net loss reported for the same period in 2024. For the six months ended June 30, 2025, the net loss was $57.2 million, compared to $55.1 million in the first half of 2024. Research and development expenses were $20.1 million for the second quarter of 2025, up from $19.5 million in Q2 2024, reflecting continued investment in product development. General and administrative expenses also increased to $8.4 million in Q2 2025 from $8.0 million in Q2 2024. The company's strategic outlook remains focused on advancing its proprietary proteomics platform towards commercialization, with no significant changes in business operations or risks noted beyond ongoing development challenges and capital requirements.

Why It Matters

For investors, Nautilus Biotechnology's continued lack of revenue and widening losses underscore the high-risk, long-term nature of its investment proposition, relying entirely on future commercialization of its proteomics platform. Employees face ongoing pressure to deliver on development milestones to justify the significant R&D spend. Customers, primarily researchers and pharmaceutical companies, are eagerly awaiting the promised high-throughput protein analysis technology, which could disrupt the competitive landscape dominated by established players like Thermo Fisher Scientific and Danaher if successfully launched. The broader market will watch to see if Nautilus can translate its scientific promise into a viable product, potentially opening new avenues in drug discovery and diagnostics.

Risk Assessment

Risk Level: high — The risk level is high because Nautilus Biotechnology, Inc. reported zero revenue for both the three and six months ended June 30, 2025, and 2024, indicating it is still pre-commercial. The company also reported net losses of $28.5 million for Q2 2025 and $57.2 million for the first half of 2025, demonstrating significant cash burn without any offsetting income.

Analyst Insight

Investors should approach NAUT with extreme caution, recognizing it as a highly speculative, pre-revenue biotechnology play. Only those with a high-risk tolerance and a long-term investment horizon should consider a position, understanding that further capital raises or significant delays in product launch could severely impact valuation.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$28.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025 or H1 2025, consistent with prior periods.)
• -$28.5M — Net Loss (Q2 2025) (Increased from -$27.9M in Q2 2024, indicating widening losses.)
• -$57.2M — Net Loss (H1 2025) (Increased from -$55.1M in H1 2024, reflecting continued operational expenses.)
• $20.1M — R&D Expenses (Q2 2025) (Up from $19.5M in Q2 2024, showing ongoing investment in product development.)
• $8.4M — G&A Expenses (Q2 2025) (Increased from $8.0M in Q2 2024, indicating higher administrative costs.)

Key Players & Entities

• Nautilus Biotechnology, Inc. (company) — filer of the 10-Q
• $28.5 million (dollar_amount) — net loss for Q2 2025
• $27.9 million (dollar_amount) — net loss for Q2 2024
• $57.2 million (dollar_amount) — net loss for six months ended June 30, 2025
• $55.1 million (dollar_amount) — net loss for six months ended June 30, 2024
• $20.1 million (dollar_amount) — research and development expenses for Q2 2025
• $19.5 million (dollar_amount) — research and development expenses for Q2 2024
• $8.4 million (dollar_amount) — general and administrative expenses for Q2 2025
• $8.0 million (dollar_amount) — general and administrative expenses for Q2 2024
• SEC (regulator) — recipient of the 10-Q filing

FAQ

Risk Factors

• Sustained Net Losses and Need for Capital [high — financial]: The company reported net losses of $28.5 million for Q2 2025 and $57.2 million for the first half of 2025. These losses are expected to continue as the company invests in its development stage proteomics platform, necessitating ongoing capital requirements.
• Development Stage Operations [high — operational]: Nautilus Biotechnology is in the development stage, with no revenue generated in the reported periods. The success of the company is contingent on the successful commercialization of its proprietary proteomics platform, which carries inherent development risks.
• Increasing Operating Expenses [medium — financial]: Research and development expenses increased to $20.1 million in Q2 2025 from $19.5 million in Q2 2024. General and administrative expenses also rose to $8.4 million from $8.0 million in the same period, indicating rising operational costs.

Industry Context

The biotechnology industry, particularly in areas like proteomics, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies in this space often operate at a loss for extended periods, relying on venture capital or public markets for funding until a product achieves commercial success.

Regulatory Implications

As a biotechnology company developing novel platforms, Nautilus faces potential regulatory scrutiny related to data integrity, product safety, and efficacy if its platform leads to diagnostic or therapeutic applications. Compliance with FDA or equivalent international bodies would be critical for future commercialization.

What Investors Should Do

1. Monitor R&D progress and key development milestones.
2. Assess cash burn rate and future funding needs.
3. Evaluate competitive landscape in proteomics.

Glossary

Proteomics Platform

A technology or system designed to study the complete set of proteins produced by an organism or system, including their structures, functions, and interactions. (This is the core technology Nautilus Biotechnology is developing, and its commercialization is critical for the company's future revenue generation.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Nautilus Biotechnology has consistently reported net losses, highlighting its development stage and reliance on external funding.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (The increase in R&D expenses reflects Nautilus's ongoing investment in advancing its proteomics platform.)

Year-Over-Year Comparison

Nautilus Biotechnology reported no revenue in Q2 2025, consistent with the prior year's Q2 2024. The net loss for Q2 2025 widened slightly to $28.5 million from $27.9 million in Q2 2024, driven by increased R&D expenses ($20.1M vs $19.5M) and higher G&A costs ($8.4M vs $8.0M). No new significant risks were highlighted beyond the ongoing development stage and capital requirements.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 31, 2025 regarding Nautilus Biotechnology, Inc. (NAUT).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR